US Edition
Artelo Biosciences Receives Patent Protection Extension in Europe
Summary by Mg Magazine – Cannabis News & Information
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Artelo Biosciences Receives Patent Protection Extension in Europe
SOLANA BEACH, Calif. — The European Patent Office (EPO) has issued a Notice of Allowance for Artelo Biosciences Inc.’s European patent application No. 21827629.3, which covers the intended commercial formulation of ART27.13, the Company’s peripherally selective cannabinoid agonist currently under evaluation in the Phase 2 CAReS trial for the treatment of cancer-related anorexia. The allowed claims protect compositions of ART27.13 dispersed in po…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
